CBX-15 Shows Promise in the Treatment of Triple-Negative Breast Cancer

Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate therapeutics, recently announced new data on CBX-15. The data show that CBX-15 is safe and highly efficacious in triple-negative breast cancer (TNBC) animal models. The antitumor efficacy of CBX-15 demonstrates its ability to enhance immunogenicity and induce immune memory through pH-based tumor targeting.

TNBC differs from other types of invasive breast cancer in that it tends to grow and spread faster, has fewer treatment options, and may have a worse prognosis.

In this exclusive interview, DocWire News spoke with Vishwas Paralkar, PhD, chief scientific officer at Cybrexa, and Sophia Gayle, PhD, director of biology at Cybrexa, about this research and its impact.